Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 837-842

  Armand, J P ^a   Extra, Y M ^b   Catimel, G ^c   Abigerges, D ^a   Marty, M ^b   Clavel, M ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; CPT 11; DNA topoisomerase I inhibitor; Dosage schedules; Irinotecan; Solid tumours

Indexed keywords

IRINOTECAN;

ARTICLE; CANCER; CLINICAL TRIAL; DIARRHEA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029857839     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010763     Document Type: Article

References (21)

1. Shimada Y, Rothenberg M, Hilsenbeck SG et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5: 202-6.
2. Kawato J, Furuta T, Aomuna M et al. Antitumor activity of a camptothecin derivative, CPT-11, against human xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
3. Tsuruo T, Matsuzaki T, Matsushita M et al. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
4. Houghton PJ, Cheshire PJ, Hallman JC et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 28: 23-9.
5. Kawato J, Aonuma M, Hiroto Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187-91.
6. Tanizawa A, Fujimori A, Fujimori Y et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836-42.
7. Abigerges D, Chabot GG, Armand J et al. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
8. Catimel G, Chabot GG, Guastalla JP et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133-40.
9. de Forni M, Bugat R, Chabot GG et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347-54.
10. Kuhn J, Burris S, Wall JG et al. Pharmacokinetics of the topoisomerase I inhibitor, SK & F 104864. Proc Am Soc Clin Oncol 1990; 9: 70.
11. Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
12. Del Bino GC, Lassoca P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991; 193: 27-35.
13. Bissery MC, Mathieu-Boue A, Lavelle F. Experimental antitumor activity of CPT-11 in vitro and in vivo. Proceedings of the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 17-20 March, 1992 (Abstr 093).
14. Furuta T, Yokokura T. Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative. Gan To Kagaku Ryoho 1990; 17: 121-30.
15. Taguchi T, Wakui A, Hasegawa K et al. Phase I clinical study of CPT-11. Gan to Kagaku Ryoho 1990; 17: 115-20.
16. Suminaga M, Hisashi F, Taguchi T et al. Phase I study of CPT-11, a derivative of camptothecin. Proceedings of the 16th International Congress of Chemotherapy (ICC) on Recent Advances in Chemotherapy, Jerusalem, 11-16 June, 1989 (Abstr).
17. Gandia D, Abigerges D, Armand JP et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196-7 (Letter).
18. Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427-36.
19. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-51.
20. Goncalves E, DaCosta L, Abigerges D et al. A new enkephalinase inhibitor, as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 1995; 13: 2144-6.
21. Gupta E, Lestingi TM, Rick R et al. Relationship of CPT-11 induced diarrhea to glucuronidation of its metabolite SN-38. Clin Res 1994; 42: 394A.